Recombinant Mutant Human Tumor Necrosis Factor Versus Cisplatin In The Treatment Of Malignant Pleural Effusions:a Meta-analysis

Objective:To evaluate the efficacy and safety of Recombinant mutant human tumor necrosis factor(rmhTNF)versus cisplatin in the treatment of malignant pleural effusions.METHODS: Databases of Pub Med,The Cochrane Library,Web of Science,Wanfang,CNKI,VIP were searched and randomized controlled trials(RCTs)on rmhTNF versus cisplatin for malignant pleural effusions were collected.The quality of RCTs was assessed by Cochrane handbook5.3.0 and Meta-analysis was carried out by Rev Man 5.3software.RESULTS: A total of 6 RCTs involving 406 patients were included.Compared with the cisplatin group,the rmhTNF group had a higher effective rate of controlling malignant effusions(RR=1.45,95%CI:1.28~1.64,P<0.000 01).As for side effects,there were no significantdifferences between the two groups in the incidences of gastrointestinal reaction,chest pain,fever,bone marrow suppression(P>0.05).CONCLUSION: Compared with cisplatin group,rmhTNF can improve the efficacy and quality of life of patients with malignant pleural effusions without increasement of adverse reactions.